Improved CHO Cell Line Stability and Recombinant Protein Expression During Long-Term Culture.

Methods Mol Biol

Faculty of Life Sciences, The University of Manchester, Michael Smith Building, Manchester, UK.

Published: February 2018

Therapeutic proteins require proper folding and posttranslational modifications to be effective and biologically active. Chinese hamster ovary (CHO) cells are by far the most frequently used host for commercial production of therapeutic proteins. However, an unpredictable decrease in protein productivity during the time required for scale up impairs process yields, time, finance, and regulatory approval for the desired product. Therefore, it is important to assess cell lines at stages throughout the period of long-term culture in terms of productivity and various molecular parameters including plasmid and mRNA copy numbers and location of the plasmid on the host cell chromosome. Here, we describe methods, which are frequently used to analyze stability of the recombinant CHO cells over long-term culture. These procedures include the following; western blotting, ELISA to evaluate protein production, real-time PCR to analyze plasmid and mRNA copy numbers, and fluorescent in situ hybridization (FISH) to assess the location of the inserted plasmid on host cell chromosomes.

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-6972-2_8DOI Listing

Publication Analysis

Top Keywords

long-term culture
12
stability recombinant
8
therapeutic proteins
8
cho cells
8
plasmid mrna
8
mrna copy
8
copy numbers
8
plasmid host
8
host cell
8
improved cho
4

Similar Publications

Non-cryo and hypothermic preservations are two available options for short-term storage of living cells. For long-term cell storage, cryopreservation is an essential procedure as it prolongs the storage time, allowing for the transport and testing of cells, as well as the establishment of cell banks. But it is unclear whether cryopreservation reduces the therapeutic effects of human umbilical cord mesenchymal stem cells (hucMSCs) on osteoarthritis (OA).

View Article and Find Full Text PDF

An Optimized Protocol for Simultaneous Propagation of Patient-derived Organoids and Matching CAFs.

Bio Protoc

January 2025

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Recurrent hormone receptor-positive (HR+) breast cancer is a leading cause of cancer mortality in women. Recurrence and resistance to targeted therapies have been difficult to study due to the long clinical course of the disease, the complex nature of resistance, and the lack of clinically relevant model systems. Existing models are limited to a few HR+ cell lines, organoid models, and patient-derived xenograft models, all lacking components of the human tumor microenvironment.

View Article and Find Full Text PDF

Introduction: Bronchiectasis is a chronic inflammatory airway disease. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), reduces pulmonary inflammation by preventing the activation of neutrophil serine proteases. In the phase II WILLOW trial, brensocatib prolonged time to first exacerbation in patients with bronchiectasis.

View Article and Find Full Text PDF

A Case of Superficial Mycoses in a Patient with Systemic Lupus Erythematosus.

Clin Cosmet Investig Dermatol

January 2025

Plastic and Cosmetic Center, The Fifth People's Hospital of Hainan Province, Haikou, Hainan, People's Republic of China.

Superficial mycoses are characterized by the infection of keratinized tissues such as the epidermis, hair, and nails. A 52-year-old woman from Hainan Province, China is reported in this study. The patient presents with large erythematous scales on her head, face, and disfigured nails over a 2-year period.

View Article and Find Full Text PDF

Refractory disease and relapse are major challenges in acute myeloid leukemia (AML) therapy attributed to survival of leukemic stem cells (LSC). To target LSCs, antibody-drug conjugates (ADCs) provide an elegant solution, combining the specificity of antibodies with highly potent payloads. We aimed to investigate if FLT3-20D9h3-ADCs delivering either the DNA-alkylator duocarmycin (DUBA) or the microtubule-toxin monomethyl auristatin F (MMAF) can eradicate quiescent LSCs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!